CIK 0001826457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Monte Rosa Therapeutics, Inc.
Sign in to watch- Ticker
- GLUE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-949-2643
- Business address
- 321 HARRISON AVENUE, SUITE 900, BOSTON, MA, 02118
- Former names
- Monte Rosa Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $137
- in 1 filing
Net −$137. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 35 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-10-05 | Bowen Matthew Principal Accounting Officer | Sale | −13 | $10.56 | $137 | 25,891 |
| 2026-07-16 | Warmuth Markus President & CEO | Sale | −9,500 | $23.18 | $220K | 585,038 |
| 2026-07-15 | Champoux Jennifer Chief Operating Officer | Option exercise 10b5-1 | +4,351 | $3.98 | $17K | 66,722 |
| 2026-07-15 | Champoux Jennifer Chief Operating Officer | Sale 10b5-1 | −4,351 | $23.38 | $102K | 62,371 |
| 2026-07-15 | Champoux Jennifer Chief Operating Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −4,351 | 26,947 | ||
| 2026-07-06 | Townson Sharon Chief Scientific Officer | Option exercise 10b5-1 | +6,000 | $6.14 | $37K | 73,845 |
| 2026-07-06 | Townson Sharon Chief Scientific Officer | Sale 10b5-1 | −5,600 | $23.25 | $130K | 68,245 |
| 2026-07-06 | Townson Sharon Chief Scientific Officer | Sale 10b5-1 | −400 | $24.13 | $10K | 67,845 |
| 2026-07-06 | Townson Sharon Chief Scientific Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,000 | 197,290 | ||
| 2026-07-01 | Behbahani Ali Director | Other disposition | −1,000,000 | 6,692,298 | ||
| 2026-07-01 | Behbahani Ali Director | Other acquisition | +15,000 | 15,000 | ||
| 2026-07-01 | Behbahani Ali Director | Other disposition | −15,000 | 0 | ||
| 2026-06-30 | Janku Filip Chief Medical Officer | Option exercise 10b5-1 | +5,407 | $13.41 | $73K | 66,019 |
| 2026-06-30 | Janku Filip Chief Medical Officer | Sale 10b5-1 | −5,407 | $24.50 | $132K | 60,612 |
| 2026-06-30 | Janku Filip Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,407 | 81,093 | ||
| 2026-06-29 | Janku Filip Chief Medical Officer | Option exercise 10b5-1 | +6,000 | $7.56 | $45K | 65,992 |
| 2026-06-29 | Janku Filip Chief Medical Officer | Sale 10b5-1 | −6,000 | $22.95 | $138K | 59,992 |
| 2026-06-29 | Janku Filip Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,000 | 60,000 | ||
| 2026-06-29 | Manning Anthony M. Director | Option exercise | +10,000 | $4.16 | $42K | 10,000 |
| 2026-06-29 | Manning Anthony M. Director | Sale | −10,000 | $23.11 | $231K | 0 |
Page 1 of 9 · 174 trades